Business
Transfer of Treasury Shares
Venture Life Group PLC announced the transfer of 257,500 ordinary shares from treasury on July 10, 2026, to settle employee stock options. Following this transaction, the total number of issued ordinary shares is 128,860,145, with 7,535,904 shares remaining in treasury, resulting in a total of 121,324,241 voting rights. This figure will serve as the denominator for shareholders calculating their notification obligations under the FCA's Disclosure and Transparency Rules. Disclaimer*
About this update from Venture Life Group Plc
13 July 2026 VENTURE LIFE GROUP PLC ("Venture Life", "VLG" or the "Group") Transfer of Treasury Shares Venture Life Group PLC (AIM: VLG), a leader in product innovation, development and commercialisation within the global consumer healthcare sector, announces that on 10 th July 2026 the Company transferred 257,500 ordinary shares of 0.3p each in the Company ("Ordinary Shares") out of treasury to settle options exercised by a number of employees in accordance with the Company's employee share option scheme. Following the transfer, the total number of Ordinary Shares in issue will be 128,860,145 , with 7,535,904 Ordinary Shares held in treasury. Therefore, the total number of voting rights will be 121,324,241 . This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules. For further information, please contact: Venture Life Group PLC +44 (0) 1344 578004 Jerry Randall, Chief Executive Officer Daniel Wells, Chief Financial Officer Cavendish Capital Markets Limited (Nomad and Broker) +44 (0) 20 7720 0500 Stephen Keys/George Lawson (Corporate Finance) Michael Johnson (Sales) About Venture Life ( www.venture-life.com ) Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle. The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK, Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.
View stock analysis, news, and events for Venture Life Group Plc